Lab-developed tests look likely to be removed from FDA oversight. That has to change, writes Walter G. Johnson.

In a recent presentation at the 25th Annual Pharmaceutical and Medical Device Ethics and Compliance Congress, Catherine Gray, the Director of the Office of Prescription Drug Promotion (OPDP) at the ...